The Gross Law Firm Reminds Baxter International, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 15, 2025 – BAX
BaxterBaxter(US:BAX) Globenewswire·2025-11-10 20:31

Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of issuing false and misleading statements regarding the safety and efficacy of its Novum LVP product, which has systemic defects leading to serious patient risks [3][4]. Summary by Sections Allegations - The complaint claims that Baxter's Novum LVP product experienced systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [3]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths related to these defects [3]. - The company's attempts to address these issues through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [3]. - There was an increased risk that customers would be advised to take existing Novum LVPs out of service, and Baxter might halt all new sales of these pumps [3]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were characterized as materially false and misleading [3]. Class Action Details - The class period for the lawsuit is from February 23, 2022, to July 30, 2025 [3]. - Shareholders are encouraged to register for the class action by December 15, 2025, to potentially become lead plaintiffs [4]. - Participation in the case does not require appointment as lead plaintiff, and there are no costs or obligations for shareholders to register [4]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [5].